why don’t we have more medicines? inventing medicines has grown less efficient, limited by our knowledge of biological targets for the 1st time, AI & genomics have the potential to make this knowledge abundant – one of the largest potential impacts of the intelligence age.

NewLimit, the anti-aging startup co-founded by Coinbase CEO @brian_armstrong, has raised $45M more from new investors like Eli Lilly's VC arm and S32. I talked with @jacobkimmel about the startup's latest research progress & timeline to the clinic:

.@newlimit has raised an additional $45M from new investors including Lilly Ventures, Duke University, @S32_VC, @AbstractVC & others. Insiders including @kleinerperkins, @_DimensionCap, @humancapital, @BoostVC also participated. This round was catalyzed by technical

i'd like to think that Akio Morita would be happy with the view from our new FACS machine the best ideas tend to emerge in beautiful places

through the late summer @newlimit, we've been upgrading our 1st prototype medicines to prepare for human trials highlights - +2 prototype medicines with efficacy in liver disease models - +14 TF payloads that restore function in old T cells - +4000 TF sets tested across

it's hard to imagine a better on ramp to the industry than working with the team @SusaVentures. highly recommended.

"A good way to understand a lot of evolution—and how you're able adapt to new environments or pathogens—is that gene duplication is possible. The real problem is this: if one or two mutations break the gene, and only three mutations together fixes it again, it’s very hard for

.@jasonjoyride is among the best emerging storytellers in science & technology excited to see him making the life sciences more legible

.@dwarkesh_sp has a rare talent for traversing the tree of ideas by stepping upon only the most entropic branches it was a joy to discuss ideas around AI in bio, human evolution, the biology of aging, @newlimit, & the future of therapeutics a few weeks back

improving biology that evolution has optimized is absurdly difficult. one reason for optimism in longevity is that evolution hardly selected for it. even simple interventions can restore function or extend life. it seems likely that medicines turning on just a few key genes can

today @newlimit, our robot fleet mixed up the latest batch of reprogramming prototypes for downstream functional testing soon, we'll need to run a few in parallel

it's clear within a few minutes of meeting that @ramtinnaimi is a force of nature loved this conversation & feel privileged to work with the @abstractvc team @newlimit

great overview of @_DimensionCap portco @newlimit, pioneering tech in epigenetic reprogramming to ̶s̶l̶o̶w̶ reverse aging in pursuit of future life saving, life extending, medicines

ashlee & the @corememory team are among the best storytellers in science. we were privileged to host them for a look inside @newlimit. we hope this is only the first of many windows into our mission to add healthy years to each life.

NewLimit paper just dropped @icmlconf showing our SOTA AI models can predict perturbed cell states. Helps to have the largest primary cell perturbation dataset in the world. Bonus points for one of the first demonstration of active learning in bio.

reprogramming has the potential unlock cell states & functions as therapeutic targets rather than single genes AI & genomics have only recently made it tractable to discover therapeutic payloads. we hope these results @newlimit are the first of many. full paper on our website

in practice, reprogramming AI is useful to prioritize which TF sets to test in laboratory experiments. we demonstrated that an active learning campaign using Ambrosia models discovered~2X as many hit payloads as a naive baseline. we also demonstrated that Bayesian sample

we discovered what we believe are some of the first scaling laws in biology at this level of complexity the performance of our Ambrosia models is directly tied to the scale of @newlimit's unique data corpus

Ambrosia performance is strong across various prediction targets (total gene expression, gene sets, orthogonal cell growth metrics) & multiple datasets (small public, large @newlimit data corpus)